inactivated influenza vaccine (Center for Human Reproduction)

The inactivated influenza vaccine is a standard biological immunization agent being investigated for a novel therapeutic application in reproductive medicine by the Center for Human Reproduction (CHR). In a Phase 4 clinical trial (NCT02947217), researchers are evaluating whether the vaccine can improve clinical pregnancy and implantation rates in women undergoing in vitro fertilization (IVF). The study is based on the hypothesis that the vaccine's stimulation of the immune system may induce pathways that favor immunological tolerance, thereby facilitating successful embryo implantation. The vaccine used is a standard inactivated formulation containing influenza virus subtype A and type B, administered intramuscularly approximately 10 days prior to embryo transfer. This investigation focuses on the vaccine's potential immunomodulatory effects on the reproductive environment, independent of its primary role in preventing seasonal influenza infection.

Other names

Influenza VaccineInfluenza Vaccination in IVF